<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04432376</url>
  </required_header>
  <id_info>
    <org_study_id>MZ-0120-ESP3-052</org_study_id>
    <nct_id>NCT04432376</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of Miconazole Oil Versus Vehicle on Fungal Infection of the Ear Canal (Otomycosis)</brief_title>
  <official_title>Randomized, Double-blind, Phase III Study of the Efficacy and Safety of Miconazole Oil Versus Vehicle Oil in the Treatment of Otomycosis, Followed by an Open-label Safety Evaluation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hill Dermaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Abond CRO Inc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hill Dermaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study involves two portions, a randomized, double-blind portion and an open-label&#xD;
      portion, to evaluate the efficacy and safety of Miconazole oil 2% versus its Vehicle in the&#xD;
      treatment of fungal infection of the outer ear canal (Otomycosis). The subjects randomized in&#xD;
      the first portion of the study will have active fungal infection of the ear(s) and will be&#xD;
      treated with either Miconazole Oil or the Vehicle for 14 days twice daily, 5 drops into the&#xD;
      ear(s) per dose. The subjects enrolled in the open-label portion of the study may or may not&#xD;
      have active fungal infection of the ear(s), and will be given the Miconazole Oil active drug&#xD;
      following the same application of 5 drops into the ear(s) twice daily for 14 days.&#xD;
&#xD;
      The intention of the study is to evaluate the efficacy of Miconazol Oil on fungal infection&#xD;
      of the ears when applied using 5 drops into the ear(s) twice daily for 14 days continuously.&#xD;
      This study also intends to show safety of Miconazole Oil 5 drops into each ear twice a day&#xD;
      for 14 consecutive days.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will be conducted in 2 portions:&#xD;
&#xD;
        1. Enrollment A, which will consist of 2 treatment periods as follows and will be conducted&#xD;
           in subjects with otomycosis:&#xD;
&#xD;
             1. A randomized, double-blind, parallel-group treatment period. This treatment period&#xD;
                will be referred to as the &quot;Randomization Period&quot; and will be followed by:&#xD;
&#xD;
             2. An optional, open-label treatment period with miconazole oil. This treatment period&#xD;
                will be referred to as the &quot;Optional Open-label Extension.&quot;&#xD;
&#xD;
        2. Enrollment B will consist of open-label treatment with miconazole oil in subjects who&#xD;
           will not be required to have signs and symptoms of otomycosis.&#xD;
&#xD;
      The study will start with Enrollment A, with an estimated 220 male or female subjects with&#xD;
      otomycosis. Subjects will be randomly assigned in a 1:1 ratio to receive miconazole oil or&#xD;
      vehicle (placebo), for 14 days. The study drug will be administered as 5 drops per ear at ~30&#xD;
      mg per drop instilled into the external ear canal of the ear(s) affected by otomycosis.&#xD;
&#xD;
      In the Randomization Period, both the subject and the investigator and study staff are&#xD;
      blinded to the contents of the study drug.&#xD;
&#xD;
      At Screening/Baseline (Day 1), assessment of the signs and symptoms of otomycosis (pruritus,&#xD;
      debris, visual examination for presence of fungal elements, and aural fullness), evaluation&#xD;
      of medical history, pregnancy screening in female of childbearing potential, and, prior and&#xD;
      concomitant medications, will be collected. Subjects with positive signs and symptoms of&#xD;
      otomycosis and who meet all eligibility criteria will enter the study. Fungal culture of&#xD;
      affected ear(s) will be taken, debris will be cleaned from the affected ear(s), and subject&#xD;
      will be randomized and study drug dispensed. Treatment will be for 14 days. Day 8 On&#xD;
      Treatment Visit will include clinical evaluation of otomycosis, cleaning of ear(s), and&#xD;
      assessment of AEs and concomitant medications, and continue treatment up to Day 14. Day 15&#xD;
      End of Treatment Visit will include clinical evaluation of otomycosis and fungal culture, AEs&#xD;
      and concomitant medications assessed. Day 22 Test of Cure Visit is an assessment of clinical&#xD;
      signs and symptoms of otomycosis and fungal culture, AEs and concomitant medications&#xD;
      assessed, and urine pregnancy test performed in women of childbearing potential.&#xD;
&#xD;
      The Optional Open-label Extension period will allow subjects to get miconazole oil for 14&#xD;
      days. No unblinding of the subject's treatment in the Randomization Period will occur at this&#xD;
      time.&#xD;
&#xD;
      For Enrollment B, male or female subjects will be enrolled to receive miconazole oil to use&#xD;
      for 14 days and will be evaluated for safety.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 8, 2020</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">November 2021</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Two phases; initial is randomized double-blind active vs placebo on a pre-determined number of subjects with otomycosis, to finish before starting second phase. Second phase is open-label use on diseased or healthy subjects to evaluate safety. Subjects from initial phase may crossover to second phase open-label if they meet the requirements, and new diseased or healthy subjects meeting requirements may enroll in this open-label phase.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>Clinical Investigators, study staff and subjects randomized to the initial phase of the study are blinded to active drug and placebo.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of subjects with Therapeutic Cure</measure>
    <time_frame>21 days from first day of drug application</time_frame>
    <description>&quot;&quot;therapeutic cure&quot; is &quot;mycological cure&quot; plus &quot;clinical cure. Mycological cure is a negative mycological culture, and clinical cure is the absence of all otomycosis signs and symptoms according to the scales for each individual sign or symptom.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with mycological cure</measure>
    <time_frame>21 days from first day of drug application</time_frame>
    <description>Negative fungal culture</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with clinical cure</measure>
    <time_frame>21 days from first day of drug application</time_frame>
    <description>Absence of all otomycosis signs and symptoms according to the scales for each individual sign or symptom</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">390</enrollment>
  <condition>Otomycosis</condition>
  <arm_group>
    <arm_group_label>Active treatment arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment with miconazole 2% oil, 5 drops into each ear twice daily for 14 consecutive days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo treatment arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Treatment with the vehicle oil, placebo, 5 drops into each ear twice daily for 14 consecutive days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Open-label treatment arm</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Application of miconazole 2% oil, 5 drops into each ear twice daily for 14 consecutive days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>miconazole 2% oil</intervention_name>
    <description>Drug treatment of otomycosis for 14 days</description>
    <arm_group_label>Active treatment arm</arm_group_label>
    <arm_group_label>Open-label treatment arm</arm_group_label>
    <other_name>active treatment</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vehicle oil</intervention_name>
    <description>Placebo treatment of otomycosis for 14 days</description>
    <arm_group_label>Placebo treatment arm</arm_group_label>
    <other_name>placebo treatment</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Randomized blinded initial phase of study:&#xD;
&#xD;
          -  Male or non-pregnant, non-lactating females with a clinical diagnosis of uncomplicated&#xD;
             otomycosis of the external ear only,&#xD;
&#xD;
          -  Intact tympanic membrane in the ear(s) to be treated with study drug,&#xD;
&#xD;
          -  In general good health as determined by medical examination and medical history,&#xD;
&#xD;
          -  Free of clinically significant disease, including diabetes mellitus, that is not&#xD;
             well-controlled or that could interfere with the study.&#xD;
&#xD;
        Open-label second phase of study:&#xD;
&#xD;
          -  Male or non-pregnant, non-lactating females with an intact tympanic membrane in the&#xD;
             ear(s) to be treated with study drug,&#xD;
&#xD;
          -  In general good health as determined by medical examination and medical history,&#xD;
&#xD;
          -  Free of clinically significant disease, including diabetes mellitus, that is not&#xD;
             well-controlled or that could interfere with the study.&#xD;
&#xD;
        Exclusion Criteria::&#xD;
&#xD;
          -  Presence of dermatoses or conditions of the ear that may interfere with evaluation of&#xD;
             otomycosis or with safety evaluations, including concomitant otic infections that&#xD;
             require antimicrobial treatment,&#xD;
&#xD;
          -  Disease that has spread beyond the external ear(s), or pre-existing skin atrophy of&#xD;
             the affected ear(s);&#xD;
&#xD;
          -  Tympanostomy tube or perforated tympanic membrane;&#xD;
&#xD;
          -  History of prior surgery directly affecting and compromising the external auditory&#xD;
             canal and/or tympanic membrane, except for prior tympanostomy tube(s) that have&#xD;
             already been removed and completely healed;&#xD;
&#xD;
          -  Use of any topical medicated treatments for otomycosis within 14 days of study entry;&#xD;
&#xD;
          -  Use of any systemic antifungal therapy within 28 days of study entry, warfarin within&#xD;
             28 days of study entry, immunosuppressive or immune-stimulating drugs within 28 days&#xD;
             of study entry, or systemic steroids within 3 months of study entry;&#xD;
&#xD;
          -  Fever of ≥100°F at study entry;&#xD;
&#xD;
          -  Otomycosis that has been unresponsive to previous antifungal treatment;&#xD;
&#xD;
          -  Known hypersensitivity to any of the components in the test formulation;&#xD;
&#xD;
          -  Participation in another investigative trial within 28 days of study entry&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>7 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arnaldo Rivera, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Missouri-Columbia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Quyen T Nguyen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UCSD</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kenneth Hodge, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Advanced ENT and Allergy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Patrick Dennis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>DelRicht Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sammy Vaught, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lake ENT &amp; FPS</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Timothy Fitzgibbon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>OnSite Clinical Solutions</affiliation>
  </overall_official>
  <overall_official>
    <last_name>John Ansley, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Carolina ENT</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Randall Ow, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>DaVinci Research LLC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Oscar DeValle, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>West Houston Clinical Research Service</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Linda Woo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Head and Neck Surgery Specialists</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Brent Benscoter, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sacramento ENT / DaVinci Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jeffrey Adelglass, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Research Your Health</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Miglena Entcheva, MD</last_name>
    <phone>616-892-3744</phone>
    <email>mentcheva@abondcro.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Carolyn Wright, MSRA</last_name>
    <phone>616-892-3765</phone>
    <email>cwright@abondcro.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Head and Neck Surgery Specialists</name>
      <address>
        <city>Chula Vista</city>
        <state>California</state>
        <zip>91910</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Linda Woo, MD</last_name>
      <phone>619-934-3260</phone>
      <email>lindatn@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Jessica Montero</last_name>
      <phone>6199343260</phone>
      <email>jess.montero@yahoo.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>UCSD</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Quyen Nguyen, MD</last_name>
      <phone>858-657-8590</phone>
      <email>Q1nguyen@health.ucsd.edu</email>
    </contact>
    <contact_backup>
      <last_name>Sharon Mick, NP</last_name>
      <phone>8586576836</phone>
      <email>smick@health.ucsd.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>DaVinci Research, LLC</name>
      <address>
        <city>Roseville</city>
        <state>California</state>
        <zip>95661</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Randall Ow, MD</last_name>
      <phone>916-736-3399</phone>
      <phone_ext>1535</phone_ext>
      <email>row@sacent.com</email>
    </contact>
    <contact_backup>
      <last_name>Rose Khalatyan</last_name>
      <phone>9163746730</phone>
      <email>rkhalatyan@davinciresearch.net</email>
    </contact_backup>
    <investigator>
      <last_name>Tim Fife, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daniel Carlton, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sacramento ENT / DaVinci Research</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95815</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brent Benscoter, MD</last_name>
      <phone>916-739-3399</phone>
      <phone_ext>1046</phone_ext>
      <email>bbenscoter@sacent.com</email>
    </contact>
    <contact_backup>
      <last_name>Marcy Adame</last_name>
      <phone>916-531-6141</phone>
      <email>madame@davinciresearch.net</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Lake ENT &amp; FPS</name>
      <address>
        <city>Leesburg</city>
        <state>Florida</state>
        <zip>34748</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sammy Vaught, MD</last_name>
      <phone>352-728-2404</phone>
      <email>sdvaught@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Hue Luong, RN</last_name>
      <phone>3527282404</phone>
      <email>Hue.lakeent@earthlink.net</email>
    </contact_backup>
    <investigator>
      <last_name>Judith Milstead</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Advanced ENT &amp; Allergy</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40220</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kenneth Hodge, MD</last_name>
      <phone>502-995-5525</phone>
      <phone_ext>1184</phone_ext>
      <email>khodge@advancedentandallergy.com</email>
    </contact>
    <contact_backup>
      <last_name>Rhonda Dase, MA</last_name>
      <phone>5029955525</phone>
      <phone_ext>1184</phone_ext>
      <email>rdase@advancedentandallergy.com</email>
    </contact_backup>
    <investigator>
      <last_name>Vasu Kakarlapudi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gregory Abbas, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Wes Allison, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Colin Neumann, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eric Carter, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Steven Shotts, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Matthew Yantis, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Keith Forwith, PhD, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andrew Gould, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Amy Ingram, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nicole Hardy, PA-C</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Grace Isaacs, PA-C</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>DelRich Research</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70816</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>DelRicht Research</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70124</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick Dennis, MD</last_name>
      <phone>504-336-2667</phone>
      <email>pdennis@delricht.com</email>
    </contact>
    <contact_backup>
      <last_name>Caitlin Simon</last_name>
      <phone>5043362667</phone>
      <email>jtaylor@delricht.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of Missouri</name>
      <address>
        <city>Columbia</city>
        <state>Missouri</state>
        <zip>65212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arnaldo Rivera, MD</last_name>
      <phone>573-884-5511</phone>
      <email>riveraal@health.missouri.edu</email>
    </contact>
    <contact_backup>
      <last_name>Rebecca Schneider</last_name>
      <phone>5738822549</phone>
      <email>schneiderri@health.missouri.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>OnSite Clinical Solutions</name>
      <address>
        <city>Dillon</city>
        <state>South Carolina</state>
        <zip>29536</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Timothy Fitzgibbon, MD</last_name>
      <phone>800-785-3150</phone>
      <phone_ext>2002</phone_ext>
      <email>TFitzgibbonMD@onsiteclinical.com</email>
    </contact>
    <contact_backup>
      <last_name>Angie Price</last_name>
      <phone>8007853150</phone>
      <phone_ext>2002</phone_ext>
      <email>aprice@onsiteclinical.com</email>
    </contact_backup>
    <investigator>
      <last_name>Robin Shealy, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Carolina ENT</name>
      <address>
        <city>Orangeburg</city>
        <state>South Carolina</state>
        <zip>29118</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Ansley, MD</last_name>
      <phone>803-536-5511</phone>
      <email>jfansley@yahoo.com</email>
    </contact>
    <contact_backup>
      <last_name>Simone Ansley</last_name>
      <phone>8035365511</phone>
      <email>Sansley700@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Lucius Craig III, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>West Houston Clinical Research Services</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77055</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oscar DeValle, MD</last_name>
      <phone>281-738-2642</phone>
      <email>odevalle@whcrs.com</email>
    </contact>
    <contact_backup>
      <last_name>Laura Bula</last_name>
      <phone>2817382642</phone>
      <email>lbula@whcrs.com</email>
    </contact_backup>
    <investigator>
      <last_name>Nixcela Ares, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Research Your Health</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>June 11, 2020</study_first_submitted>
  <study_first_submitted_qc>June 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 16, 2020</study_first_posted>
  <last_update_submitted>August 23, 2021</last_update_submitted>
  <last_update_submitted_qc>August 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Otomycosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Miconazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

